Effects of typical and atypical antipsychotics on glucose–insulin homeostasis and lipid metabolism in first-episode schizophrenia

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Psychopharmacology

• Publication date

  2006-04-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00213-006-0384-5PMID 16601995
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Disturbed glucose metabolism among patients taking olanzapine and typical antipsychotics.

  2025cited by this paper
• Atypical antipsychotics and glucose homeostasis.

  2005cited by this paper
• Correlation of serum ghrelin levels with body mass index and carbohydrate metabolism in patients treated with atypical antipsychotics.

  2005cited by this paper
• Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

  2005cited by this paper
• Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic

  2005cited by this paper
• Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients.

  2005cited by this paper
• Actions of antipsychotic drugs on pancreatic β-cell function: contrasting effects of clozapine and haloperidol

  2005cited by this paper
• Antipsychotic medication and diabetes mellitus.

  2005cited by this paper
• A crossover study on lipid and weight changes associated with olanzapine and risperidone

  2005cited by this paper
• Clozapine and olanzapine, but not conventional antipsychotics, increase insulin release in vitro.

  2004cited by this paper
• Atypical Antipsychotics and Metabolic Dysregulation: Evaluating the Risk/Benefit Equation and Improving the Standard of Care

  2004cited by this paper
• The effect of clozapine on factors controlling glucose homeostasis.

  2004cited by this paper
• Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.

  2004cited by this paper
• Guidelines for prevention and treatment of adverse effects of antipsychotic drugs on glucose–insulin homeostasis and lipid metabolism

  2004cited by this paper
• A simple and reliable conflict procedure for testing anti-anxiety agents

  2004cited by this paper
• The increase in risk of diabetes mellitus from exposure to second-generation antipsychotic agents.

  2004cited by this paper
• Long-term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance: 4-year results from the Finnish Diabetes Prevention Study.

  2003cited by this paper
• Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.

  2003cited by this paper
• Weight Change after an Atypical Antipsychotic Switch

  2003cited by this paper
• Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition.

  2002cited by this paper
• Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia.

  2002cited by this paper
• Interventions for Weight Gain in Adults Treated With Novel Antipsychotics.

  2000cited by this paper
• Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses.

  2000cited by this paper
• Antipsychotic-induced weight gain: a comprehensive research synthesis.

  1999cited by this paper
• Development of the multiple metabolic syndrome: an epidemiologic perspective.

  1998cited by this paper
• The Homeostasis Model in the San Antonio Heart Study

  1997influential reference
• Severe hyperglycemia associated with high doses of clozapine.

  1994cited by this paper
• Hyperglycemic properties of serotonin receptor antagonists.

  1991cited by this paper
• Induction of Obesity by Psychotropic Drugs

  1987cited by this paper

• A Comparative Follow-up Study of Metabolic Syndrome in Schizophrenia Patients Treated with Olanzapine and Risperidone

  2026cites this paper
• Metabolic syndrome with different antipsychotics: a multicentre cross-sectional study.

  2025cites this paper
• Examining the safety profile of clozapine versus other antipsychotics: systematic review and meta-analysis.

  2025cites this paper
• Clozapine impaired glucose-stimulated insulin secretion partly by increasing plasma 5-HT levels due to the inhibition of OCT1-mediated hepatic 5-HT uptake in mice

  2024cites this paper
• Effects of atypical antipsychotics on serum asprosin level and other metabolic parameters in patients with schizophrenia

  2024cites this paper
• Assessing Effects of Diet Alteration on Carbohydrate–Lipid Metabolism of Antipsychotic-Treated Schizophrenia Patients in Interventional Study

  2023cites this paper
• Clinical improvement in schizophrenia during antipsychotic treatment in relation to changes in glucose parameters: A systematic review.

  2023cites this paper
• Dance/movement therapy for improving balance ability and bone mineral density in long-term patients with schizophrenia: a randomized controlled trial

  2023cites this paper
• Coadministration of olanzapine causes minor impacts on the diabetogenic outcomes induced by dexamethasone treatment in rats.

  2023cites this paper
• Weight Gain and Metabolic Changes in Patients With First-Episode Psychosis or Early-Phase Schizophrenia Treated With Olanzapine: A Meta-Analysis

  2023cites this paper
• Assessment of Plasma Glucose and Lipid Profile Dysregulation among Patients on Antipsychotics in Sokoto

  2022cites this paper
• Metabolic derangements with olanzapine and risperidone in schizophrenia spectrum and other psychotic disorders: A 24-week prospective study

  2022cites this paper
• Homocysteine Levels and Clinical Outcomes in Schizophrenia—A Pilot Randomized Controlled Trial

  2022cites this paper
• Blood and Urinary Biomarkers of Antipsychotic-Induced Metabolic Syndrome

  2022cites this paper
• NDT_A_305200 1289..1297

  2021cites this paper
• Association Between ApoA1 Gene Polymorphisms and Antipsychotic Drug-Induced Dyslipidemia in Schizophrenia

  2021cites this paper
• Olanzapine leads to nonalcoholic fatty liver disease through the apolipoprotein A5 pathway

  2021cites this paper
• Interventions for preventing type 2 diabetes in adults with mental disorders in low- and middle-income countries.

  2021cites this paper
• The metabolic effects of antipsychotics in the early stage of treatment in first-episode patients with schizophrenia: A real-world study in a naturalistic setting.

  2020cites this paper
• Effects of olanzapine treatment on lipid profiles in patients with schizophrenia: a systematic review and meta-analysis

  2020cites this paper
• Association of selected antipsychotics on the triglyceride levels in patients with schizophrenia in inpatient and outpatient settings

  2020cites this paper
• Reduced Levels and Disrupted Biosynthesis Pathways of Plasma Free Fatty Acids in First-Episode Antipsychotic-Naïve Schizophrenia Patients

  2020cites this paper
• Metabolic effects of aripiprazole and olanzapine multiple-dose treatment in healthy volunteers. Association with pharmacogenetics

  2020cites this paper
• Assessing effects of diet alteration on selected parameters of chronically mentally ill residents of a 24-hour Nursing Home. Part I: Effects of diet modification on carbohydrate-lipid metabolism.

  2020cites this paper
• Metabolic Effects of Aripiprazole and Olanzapine Multiple-Dose Treatment in a Randomised Crossover Clinical Trial in Healthy Volunteers: Association with Pharmacogenetics

  2020cites this paper
• Effects of risperidone on glucose lipid metabolism and bodyweight in drug-naïve first episode Chinese Han patients with schizophrenia: A prospective study

  2019cites this paper
• The Effects of Two Novel Anti-Inflammatory Compounds On Prepulse Inhibition and Neural Microglia Cell Activation in a Rodent Model of Schizophrenia

  2019influential citation
• Association of First- vs. Second-Generation Antipsychotics with Lipid Abnormalities in Individuals with Severe Mental Illness: A Systematic Review and Meta-Analysis

  2019cites this paper
• Switching to paliperidone extended release in patients with schizophrenia dissatisfied with previous olanzapine treatment

  2019cites this paper
• Role of tissue plasminogen activator and plasminogen activator inhibitor as potential biomarkers in psychosis.

  2019cites this paper
• Metabolic Side Effects of Antipsychotic Medication: An Overview

  2019cites this paper
• Adverse drug reactions of antipsychotic drug treatment – how to balance evidence and values in relation to the use of clozapine in treatment-resistant schizophrenia

  2018cites this paper
• Higher schizotypy predicts better metabolic profile in unaffected siblings of patients with schizophrenia

  2018cites this paper
• Initial Clinical Experience of RP5063 Following Single Doses in Normal Healthy Volunteers and Multiple Doses in Patients with Stable Schizophrenia

  2018cites this paper
• Brilaroxazine (RP5063) Clinical Experience in Schizophrenia: "A New Option to Address Unmet Needs"

  2018cites this paper
• The prevalence, risk factors and clinical correlates of obesity in Chinese patients with schizophrenia.

  2017cites this paper
• Har klozapin eller olanzapin högre risk för metabola biverkningar

  2017influential citation
• Risk of diabetes and dyslipidemia during clozapine and other antipsychotic drug treatment of schizophrenia in Iceland

  2017cites this paper
• The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis

  2017cites this paper
• Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome

  2017cites this paper
• Evaluating an individualized lifestyle and life skills intervention to prevent antipsychotic‐induced weight gain in first‐episode psychosis

  2016cites this paper
• Psychosis, antipsychotics and premature mortality: The elephant in the room

  2016cites this paper
• Risk of New-Onset Diabetes After Long-Term Treatment With Clozapine in Comparison to Other Antipsychotics in Patients With Schizophrenia

  2016cites this paper
• Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials

  2016cites this paper
• Level of Insulin Resistance in Schizophrenia Patients and Its Association with Treatment with Antipsychotics

  2016cites this paper
• Metabolic abnormalities among people diagnosed with schizophrenia: a literature review and implications for mental health nurses.

  2015cites this paper
• Complement 3 and metabolic syndrome induced by clozapine: a cross-sectional study and retrospective cohort analysis

  2015cites this paper
• Effects of LEP, LEPR, ADIPOQ, MC4R and FTO polymorphisms on dyslipidemia in Korean patients with schizophrenia who are taking clozapine.

  2015cites this paper
• Early Intervention in the Real World Evaluating an individualized lifestyle and life skills intervention to prevent antipsychotic-induced weight gain in first-episode psychosis

  2015cites this paper
• Understanding of Antipsychotics in Elderly Patients with Dementia

  2015cites this paper
• Increased Risk of Obesity and Metabolic Dysregulation following 12 Months of Second-Generation Antipsychotic Treatment in Children: A Prospective Cohort Study

  2015cites this paper
• Syndrome métabolique chez les patients schizophrènes sous antipsychotiques : analyse de la prise en charge au Centre Hospitalier Pierre Janet du Havre

  2015cites this paper
• Ensuring the Safety of Children Treated with Second-Generation Antipsychotics

  2015cites this paper
• Incident users of antipsychotic agents and future use of cholesterol-lowering drugs: an observational, pharmacoepidemiologic study.

  2015cites this paper
• Zbrinjavanje kardiovaskularnih čimbenika rizika u bolesnika s teškim psihičkim bolestima

  2015cites this paper
• Olanzapine in Chinese patients with schizophrenia or bipolar disorder: a systematic literature review

  2014cites this paper
• The Effectiveness of a Computer Reminder System for Laboratory Monitoring of Metabolic Syndrome in Schizophrenic Outpatients Using Second-generation Antipsychotics

  2014cites this paper
• Clozapine safety, 40 years later.

  2014cites this paper
• Use and Safety of Antipsychotics in Behavioral Disorders in Elderly People With Dementia

  2014cites this paper
• Glucometabolic hormones and cardiovascular risk markers in antipsychotic-treated patients.

  2014cites this paper
• Metabolic syndrome in patients taking clozapine: prevalence and influence of catechol-O-methyltransferase genotype

  2014cites this paper
• Metabolic syndrome among psychiatric outpatients with mood and anxiety disorders

  2014cites this paper
• Sulpiride versus placebo for schizophrenia.

  2014cites this paper
• Management of Medication-Related Adverse Effects

  2014cites this paper
• Medical and Psychiatric Comorbidities: Complicating Treatment Expectations

  2014cites this paper
• Metabolic changes caused by first generation antipsychotic versus second generation antipsychotic in schizophrenic patients

  2013cites this paper
• A meta‐analysis of cardio‐metabolic abnormalities in drug naïve, first‐episode and multi‐episode patients with schizophrenia versus general population controls

  2013cites this paper
• Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis.

  2013influential citation
• Effects of prenatal exposure to atypical antipsychotics on postnatal development and growth of infants: a case-controlled, prospective study

  2013cites this paper
• Comparative Safety of Antipsychotics: Another Look at the Risk of Diabetes

  2013cites this paper
• The comparison of glycometabolism parameters and lipid profiles between drug-naïve, first-episode schizophrenia patients and healthy controls.

  2013cites this paper
• Metabolic syndrome in schizophrenia: Differences between antipsychotic-naïve and treated patients

  2013cites this paper
• Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis.

  2013cites this paper
• [Risk factors associated with metabolic abnormalities in first-episode psychotic patients. A systematic review].

  2013cites this paper
• Poster #13 RECEPTOR BINDING PROFILES OF ANTIPSYCHOTIC MEDICATIONS AND GLUCOSE DYSREGULATION: AN ACUTE ANIMAL MODEL

  2012cites this paper
• The incidence and relative risk of stroke in patients with schizophrenia: a five-year follow-up study.

  2012cites this paper
• Comparing tolerability profile of second generation antipsychotics in schizophrenia and affective disorders : a meta-analysis

  2012cites this paper
• Comparing Tolerability of Olanzapine in Schizophrenia and Affective Disorders

  2012cites this paper
• World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance

  2012cites this paper
• Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study.

  2012cites this paper
• The impact of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) on prescribing practices: an analysis of data from a large midwestern state.

  2012cites this paper
• Deterioration of metabolic parameters during short-term psychiatric inpatient treatment: A prospective naturalistic study

  2012cites this paper
• Prevalence of baseline lipid monitoring in patients prescribed second-generation antipsychotics during their index hospitalization: a retrospective cohort study.

  2012cites this paper
• Health Information Preference among Youth and Caregivers related to Second-Generation Antipsychotic Treatment.

  2012cites this paper
• Weight gain and metabolic side effects with antipsychotic drugs in children

  2012cites this paper
• Waist Circumference is a Sensitive Screening Tool for Assessment of Metabolic Syndrome Risk in Children Treated with Second-Generation Antipsychotics

  2012cites this paper
• Antipsychotic medication for early episode schizophrenia.

  2011cites this paper
• Effectiveness of maintenance treatments with atypical and typical antipsychotics in stable schizophrenia with early stage: 1-year naturalistic study

  2011cites this paper
• Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis.

  2011cites this paper
• Atypical antipsychotics and the neural regulation of food intake and peripheral metabolism.

  2011cites this paper
• A potential role for adjunctive vitamin D therapy in the management of weight gain and metabolic side effects of second-generation antipsychotics

  2011cites this paper
• Barriers and facilitators to implementation of a metabolic monitoring protocol in hospital and community settings for second-generation antipsychotic-treated youth.

  2011cites this paper
• Blocking Dopamine D2 Receptors by Haloperidol Curtails the Beneficial Impact of Calorie Restriction on the Metabolic Phenotype of High‐Fat Diet Induced Obese Mice

  2011cites this paper
• Genetic Polymorphisms in the HTR2C and Peroxisome Proliferator-Activated Receptors Are Not Associated with Metabolic Syndrome in Patients with Schizophrenia Taking Clozapine

  2011cites this paper
• Onset of action of atypical and typical antipsychotics in the treatment of adolescent schizophrenic psychoses.

  2011cites this paper
• Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long‐acting injection versus oral olanzapine

  2011cites this paper
• Clozapine safety, 35 years later.

  2011cites this paper
• Triglyceride/high-density lipoprotein cholesterol ratio: a surrogate to predict insulin resistance and low-density lipoprotein cholesterol particle size in nondiabetic patients with schizophrenia.

  2011cites this paper
• Liver function tests in children and adolescents receiving risperidone treatment for a year: A longitudinal, observational study from Turkeya

  2011cites this paper
• Effect of Antipsychotic Medications on Glucose and Lipid Levels

  2011cites this paper